| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Anesthesiology, Tulane Health Sciences Center, New Orleans, Louisiana, USA.
Address correspondence to: Dr. Corey S. Scher, Department of Anesthesiology, Tulane Health Sciences Center, 1415 Tulane Ave. SL-4, New Orleans, LA 70112, USA. Phone: 504-588-5903, Fax: 504-584-1941; E-mail: cscher{at}anes.tulane.edu
| Abstract |
|---|
|
|
|---|
Clinical features: A 52-yr-old male with prostate cancer presented for radical prostatectomy. He reported several failed intubations with previous surgeries and airway examination was consistent with a difficult intubation. In addition, previous fibreoptic intubations were unsuccessful. The patient reported extreme apprehension concerning his airway management.
The goal of medicating patients for AFOI includes providing comfort and sedation without causing a change in ventilatory status. Dexmedetomidine has a high affinity for the alpha2 receptor and results in sedation without change in ventilatory status. In addition, dexmedetomidine is a potent anti-sialgogue which makes it desirable for cases involved with airway instrumentation. A loading dose of dexmedetomidine followed by a continuous infusion provided comfort and sedation within ten minutes. While bradycardia and hypotension have been reported with dexmedetomidine use, concurrent low-dose ketamine was employed in this case for its cardiostimulatory properties and no bradycardia and hypotension were noted. The airway was anesthetized with selective nerve blocks and conditions for airway instrumentation were excellent. There was no change in oxygen saturation or ventilatory status during the administration of medications or airway manipulation. The patient was comfortable, sedated and tolerated the procedures well. There was no recall of the procedure.
Conclusion: Dexmedetomidine and concurrent low-dose ketamine provided sedation and comfort to this patient who required an AFOI.
| Introduction |
|---|
|
|
|---|
| Case report |
|---|
|
|
|---|
We contacted the institution where his previous surgery was cancelled and obtained a copy of his anesthetic record, which supported the patients description of the events in the operating room. In addition, the record revealed difficulty ventilating his lungs with both a number 4 and 5 laryngeal mask airway. During his preoperative assessment, the patient expressed severe apprehension and anxiety concerning management of his airway.
On physical examination, the patient was 1.6 m tall and weighed 81 kg. Blood pressure was 132/78 and pulse was 82 beatsmin-1. Physical examination exclusive of the airway was remarkable only for multiple scars on his back extending from T6L5. Airway examination revealed a thyromental distance of 2.5 cm, a Mallampati score of 4, and a mildly receding mandible. There were no protruding teeth and dentition was excellent. The patients mouth opening was in excess of 40 mm and neck range of motion was normal.
In the preoperative holding area, members of the anesthesia care team counselled the patient. An iv line was inserted, and, despite requests from the patient, no sedation was administered prior to entry into the operating room. Members of the otolaryngology service were notified and were immediately available. The anesthetic plan included evaluation of the airway with direct laryngoscopy and fibreoptic intubation if the vocal cords could not be visualized.
Electrocardiogram, blood pressure cuff and a pulse oximeter were applied and the patient was informed concerning these plans. The patient was instructed that we would not proceed with our evaluation and intubation until he was comfortable. The plan for sedation and comfort included infusions of the alpha2 agonist, dexmedetomidine and low-dose ketamine.
The patient received a bolus of dexmedetomidine 1 µgkg-1 (Precedex-Abbott Laboratories, North Chicago, IL, USA) over ten minutes. After the bolus, the infusion was set at 0.7 µgkg-1hr-1. Neither hypotension or bradycardia were noted during dexmedetomidine administration. The patient reported comfort and sedation at the termination of the loading dose. The patient was rousable at all times, but when left unstimulated, tended to sleep. No changes in oxygen saturation and respiration were noted during the bolus or maintenance infusion. Upon completion of the dexmedetomidine bolus, 15 mg of ketamine were administered as a bolus and an infusion of 20 mghr-1 was initiated. After the ketamine bolus, and during the infusion, the patient reported that he was calm, comfortable, sedated and stated that he was ready for the fibreoptic intubation. This low dose of ketamine did not result in adverse changes in mental status. There continued to be no change in oxygen saturation and respiratory status. He did complain of dry mouth.
During the continuous drug infusion, blocks of the recurrent laryngeal nerve and internal branch of the superior laryngeal nerve bilaterally were performed in the usual manner.1 The tongue and hypopharynx were sprayed with benzocaine. The patient remained both sedated and cooperative during these blocks. A Macintosh laryngoscope (#4 blade) was inserted and the patient remained very cooperative although the epiglottis and vocal cords were not visualized.
An endoscopic oral airway was placed in the mouth and fibreoptic intubation was performed. The endoscopist noted excellent conditions including a secretion free airway. The patient was able to respond to requests to take slow, large deep breaths. The epiglottis and vocal cords were visualized and intubation proceeded without difficulty. General anesthesia was then induced and the drug infusions were discontinued. After an uncomplicated surgery, the trachea was extubated after the patient met criteria for extubation. The patient had no recall of the nerve blocks, direct laryngoscopy, or fibreoptic intubation.
| Discussion |
|---|
|
|
|---|
Dexmedetomidine, an alpha2 agonist, is an effective sedative and analgesic agent widely used for patients requiring postoperative ventilation in the intensive care unit.6 Dexmedetomidine sedation does not cause respiratory depression.7 In addition, xerostomia is commonly reported by patients. These two effects make dexmedetomidine highly desirable for AFOI. The characteristics of dexmedetomine sedation have been compared to propofol in the intensive care setting.8,9 Unlike patients sedated with propofol, patients receiving dexmedetomidine are easily roused to cooperate with medical procedures without expressing irritation. This quality is helpful when patients are asked to take deep inspirations or clear secretions during fibreoptic intubation. The relative sympatholysis achieved during dexmedetomidine infusions is an additional benefit in a procedure that may lead to elevations of heart rate and blood pressure. While bradycardia and hypotension have been reported with dexmedetomidine, this was not observed in this patient receiving a concurrent ketamine infusion.10 In this case, the patient did not recall fibreoptic intubation. While lowering of bispectral index scores and partial amnesia have been reported11 the true amnestic qualities of dexmedetomidine have yet to be defined. The coexisting infusion of ketamine may have contributed to the amnesia observed in this case.12
Ketamine was selected to take advantage of its minimal impact on ventilatory drive and analgesic properties. The undesirable feature of increased airway secretions with ketamine administration was attenuated by the xerostomia induced by dexmedetomidine. In addition, dexmedetomidine attenuates ketamine-induced cardiostimulatory effects and drug-induced delirium.13 The patient did not report hallucinations nor vivid dreams. The initial loading dose of 15 mg and infusion of 20 mghr-1 is considered a low dose by most clinicians. It has been suggested that low-dose ketamine infusion (4 ugkg-1min-1), effectively lowers postoperative narcotic requirements without significant effect on mood, perception and cognition.12
While the interactions of dexmedetomidine and ketamine on ventilatory drive, analgesia, sedation, amnesia, and cardiovascular variables remain unclear, this combination did provide us with excellent conditions for AFOI, including satisfactory sedation, patient cooperation and a dry airway.
Revision received March 3, 2003. Accepted for publication November 28, 2002.
| References |
|---|
|
|
|---|
2 Bailey PL, Pace NL, Ashburn MA, Moll JW, East KA, Stanley TH. Frequent hypoxemia and apnea with sedation with midazolam and fentanyl. Anesthesiology 1990; 73: 82630.[Medline]
3 Kallos T, Smith TC. The respiratory effects of Innovar given for premedication. Br J Anaesth 1969; 41: 3036.
4 Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62: 164971.[Medline]
5 Ben-David B, Weber S, Chernus S. Droperidol "box warning" warrants scrutiny (Letter). Anesthesiology 2002; 97: 288.
6 Venn RM, Bradshaw CJ, Spencer R, et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 1999; 54: 113642.[Medline]
7 Belleville JP, Ward DS, Bloor BC, Maze M. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology 1992; 77: 112533.[Medline]
8 Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth 2001; 87: 68490.
9 Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg 2000; 90: 699705.
10 Hogue CW Jr, Talke PK, Stein P, Richardson C, Domitrovich PP, Sessler DI. Autonomic nervous system responses during sedative infusions of dexmedetomidine. Anesthesiology 2002; 97: 5928.[Medline]
11 Mortero RF, Clark LD, Tolan MM, Metz RJ, Tsueda K, Sheppard RA. The effects of small-dose ketamine on propofol sedation: respiration, postoperative mood, perception, cognition, and pain. Anesth Analg 2001; 92: 14659.
12 Levanen J, Makella ML, Scheinin H. Dexmedetomidine premedication attenuates ketamine-induced cardiostimulatory effects and postanesthetic delirium. Anesthesiology 1995; 82: 111725.[Medline]
13 Suzuki M, Tsueda K, Lansing PS, et al. Small-dose ketamine enhances morphine-induced analgesia after outpatient surgery. Anesth Analg 1999; 89: 98103.
This article has been cited by other articles:
![]() |
M. R. Rai, T. M. Parry, A. Dombrovskis, and O. J. Warner Remifentanil target-controlled infusion vs propofol target-controlled infusion for conscious sedation for awake fibreoptic intubation: a double-blinded randomized controlled trial Br. J. Anaesth., January 1, 2008; 100(1): 125 - 130. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |